Please assess the completion status of the following clinical trial:

Trial Title: Lansoprazole Preventing Gastroduodenal Stress Ulcerations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Patients with symptomatic coronary artery disease or valvular heart disease who require corrective cardiac surgery will be eligible to participate in this study.~Inclusion Criteria:~* Patients undergoing cardiovascular surgery, specifically elective coronary artery bypass graft or cardiac valve replacement surgery, at Temple University Hospital~* Able to provide informed consent~Exclusion Criteria:~* Evidence of active gastrointestinal bleeding~* Prior gastric (e.g. Billroth II) or esophageal surgery~* Pregnancy~* Pre-existing or current condition requiring acid-suppressive therapy - e.g. reflux esophagitis, gastric or duodenal ulcer~* Current use of acid-suppressive therapy, such as proton pump inhibitors or histamine type 2 receptor antagonists~* Contraindication to naso- or oro-gastric intubation (e.g. Zenker's diverticulum, esophageal stricture)~* Bleeding diathesis~* Allergy to lansoprazole~* Advanced renal disease (BUN\>40 and/or creatinine\>2.0.~* Advanced liver disease (Alkaline phosphatase, ALT, AST\>2 x normal)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).